Advanced Topics in Multidisciplinary Cancer Care in Renal cell Carcinoma Online Educational Event.
Renal cell carcinoma (RCC) affects more than 50,000 people in the United States yearly, with more than 10,000 patients still dying of their disease despite many advances in surgery and systemic therapy. Several phase III clinical trials have been recently published, bringing new treatment options for patients with locally advanced and metastatic disease. The use of immunotherapy has moved from second line setting to first line setting. Combinations of immunotherapeutic agents are now standard of care, and combinations of immunotherapy with antiangiogenic agents are currently undergoing clinical investigation.
In this educational session we will review recent advances and changes in the care of patients with renal cell carcinoma. Specific topics to be covered include:
- Role of neoadjuvant/presurgical therapy for RCC.
- Updates on adjuvant therapy use in RCC.
- Updates on management of patients with metastatic RCC with primary tumor in place/role of cytoreductive nephrectomy.
- Management of patients with non-clear cell RCC.
|10:00 - 10:10 am (GMT – 6)||
|10:00 - 10:40 am (GMT – 6)||
Jose A. Karam, MD, FACS
|10:40 - 11:40 am (GMT – 6)||
Multidisciplinary approach to the management of Genitourinary Cancers
Christopher G. Wood, MD, FACS
Nizar Tannir, MD, FACP
Matthew Campbell, MD
|11:40 - 12:00 am (GMT – 6)||
|12:00 am (GMT – 6)||